P
143.78
3.87 (2.76%)
| Previous Close | 139.91 |
| Volume | 474,759 |
| Price / Earnings (Forward) | 36.90 |
| Price / Sales | 33.15 |
| Price / Book | 10.67 |
| 52 Weeks Range |
| Profit Margin | 27.04% |
| Operating Margin (TTM) | -68.18% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | -88.90% |
| Quarterly Earnings Growth (YOY) | 381.70% |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 17.25 |
| Operating Cash Flow (TTM) | 336.94 M |
| Levered Free Cash Flow (TTM) | 327.76 M |
| Return on Assets (TTM) | 2.48% |
| Return on Equity (TTM) | 8.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Protagonist Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.05 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.10% |
| % Held by Institutions | 108.49% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALI ASIF | - | 140.89 | -58,629 | -8,260,240 |
| Aggregate Net Quantity | -58,629 | |||
| Aggregate Net Value ($) | -8,260,240 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 140.89 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ALI ASIF | Officer | 30 Sep 2026 | Automatic sell (-) | 58,629 | 140.89 | 8,260,240 |
| ALI ASIF | Officer | 30 Sep 2026 | Option execute | 58,629 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |